<DOC>
	<DOCNO>NCT03003273</DOCNO>
	<brief_summary>Pediatric patient febrile neutropenia come Department Medical Oncology low risk feature ( culture await ) , start intravenous antibiotic ( Inj Cefoperazone+ Sulbactam ± Amikacin ) outpatient basis . Those patient reassess randomization fulfill inclusion criterion get afebrile least 24 hour . Antibiotics stop Arm-A oral antibiotic , place intravenous antibiotic , start Arm-B . The patient followed-up till ANC≥ 500 , reappearance fever within follow-up ≤ 10 day .</brief_summary>
	<brief_title>Early Stoppage Versus Continuation Antimicrobial Therapy Low Risk Pediatric Cancer Patients With Febrile Neutropenia , Before Recovery Counts : -DALFEN Study</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Clavulanic Acids</mesh_term>
	<mesh_term>Clavulanic Acid</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>All pediatric febrile neutropenia patient treat outpatient basis Age 3 year 18 year Fulfilling low risk criterion ( Hematological malignancy remission , No identifiable focus infection , No Pneumonia/ mucositis / GI sepsis / Nauseavomiting/ neurologicmental status changes/ Central Venous Catheter ( CVC ) relate infection , Anticipated Absolute Neutrophil Count ( ANC ) recovery ≤ 10 day , No organ dysfunction , Hemodynamically stable , Culture negative ) Afebrile least 24 hour , intravenous antibiotic Bone marrow involvement solid tumor Already enrol , previous episode On antibiotic prophylaxis Retroviral positive patient Patient undergone stem cell transplant</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>